Skip to main content

Pharmaceutical Companies Explore New AI Applications

How can artificial intelligence (AI) technology improve traditional medicine? With 97 percent of all drug discovery programs reportedly failing, the development of a single new therapeutic involves an average cost of $2.6 billion. Helping to improve that process is a huge upside opportunity.

Today, the complex research framework that's involved in the discovery and development of new therapeutic products makes drug innovation an extremely laborious process, according to the latest worldwide market study by Frost & Sullivan.

Pharmaceutical AI Market Development

More than 60 percent of known diseases remain untreatable. Meanwhile, life sciences companies are making progress in the fields of gene and cell therapies, omics technologies, and smart molecules approaches, creating the need for advanced, cost-effective technologies that can parse large quantities of data.

"Pharmaceutical companies are increasingly recognizing the value of deploying AI-based platforms that can leverage data regarding gene mutations, protein targets, signaling pathways, disease events, and clinical trials to find hidden drug-disease correlations,” said Cecilia Van Cauwenberghe, senior analyst at Frost & Sullivan.

This technology will enable scientists to derive structured and unstructured data from multiple sources as never before. Moreover, strategic collaborations with IT vendors can help pharmaceutical companies establish a robust, AI-based pipeline as part of their portfolios and address new therapeutic areas.

AI-driven tools are encouraging companies to develop therapies for severely underserved areas and are also paving the way for precision medicine through a stratified therapeutics discovery and development approach.

Collaborations among database holders, AI developers, and drug manufacturers will facilitate the early development of multiple therapeutics, even those focused on treating rare and chronic diseases.

The leading companies are also empowered to make the most of scientific results and learning systems synergy to ensure a successful clinical translation of therapeutic, diagnostic, and theranostic developments. Some of the key applications of AI technologies in pharmaceuticals include:

  • Drug development: Aids in disease modeling, drug design and development, lead identification, and drug repurposing.
  • Candidates validation: Helps design and run pre-clinical trials, in silico/in vitro/in vivo studies, and investigational new drug (IND) process.
  • Clinical trials: Supports all processes, from designing the trial to patient identification through data collection, analysis, and report generation.
  • Regulatory approval: Facilitates the approval of application and process, labeling, and safety updates.
  • Precision medicine: Accelerates the development of preventive and personalized care, treatment surveillance, and omics adaptive models.

Outlook for Medical AI Application Growth

"Overall, there is a profound and growing scientific understanding of many metabolic and signaling pathways, especially at molecular and genomic levels, which encourages the use of sophisticated technologies to develop groundbreaking therapies," noted Van Cauwenberghe.

As the underlying causes of many diseases remain vague and imprecise, artificial intelligence-oriented approaches have emerged as the ideal mechanisms for finding novel treatments.

Popular posts from this blog

Digital Transformation Investment at $3.4 Trillion

Business technology leadership matters. Across the globe, more leaders have been pursuing bold Digital Transformation (DX) initiatives with the goal of creating new sources of business value through digital products, services, and experiences. As an additional benefit, the COVID-19 pandemic revealed that digital transformation efforts improve an organization's resilience against global market disruptions. Global DX investment is forecast to reach $3.4 trillion in 2026 with a five-year compound annual growth rate (CAGR) of 16.3 percent, according to the latest worldwide market study by International Data Corporation (IDC). Digital Transformation Market Development "Despite strong headwinds from global supply chain constraints, soaring inflation, political uncertainty, and an impending recession, investment in digital transformation is expected to remain robust," said Craig Simpson, senior research manager at IDC . The benefits of investing in DX technology -- including aut

Artificial Intelligence for National Border Security

National border protection agencies are under pressure to provide the highest level of security in the face of growing threats, such as increasing illegal migration and international terrorism. Now, government agencies are embracing advanced border security technologies to aid in effectively and reliably securing national borders. These solutions look to detect and identify potential threats and prevent them from escalating to a point that may jeopardize security. Security Surveillance Market Development Traditional border security patrols and Closed-circuit Television (CCTV) surveillance systems aren't adequate protection, and agencies must increasingly deploy new solutions to stay ahead of criminals and other potential threats to ensure the safety of a country’s borders. According to the latest market study by Juniper Research, the value of the border security technology market will exceed $70 billion globally in 2027 -- that's rising from $48 billion in 2022. Growing by 47 p

Precision Medicine Spend to Reach $132.3 Billion

Precision Medicine uses molecular info to extract the optimum medical method from diagnostic protocols, by merging the impact of environmental and genetic factors. Data access is essential, with genetic metabolic and clinical data used to build a fuller picture of a patient's biology. Moreover, the primary aim of precision medicine is to design and optimize a pathway for diagnosis, therapeutic intervention, and prognosis, using large biological datasets. Personalized, evidence-based medicine uses stored health data, which includes patient diagnosis, laboratory work, insurance claims, and demographic information. The results enable healthcare providers to predict and prevent some illnesses. Precision Medicine Market Development According to the latest worldwide market study by Juniper Research, the total investment in precision medicine will reach $132.3 billion globally by 2027 -- that's increasing from only $35.7 billion in 2022. The significant market growth of 270 percent is